Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension

被引：0
|
作者：
Reinisch, W. [1 ,2 ,3 ,4 ]
Gibson, P. [5 ]
Sandborn, W. J. [6 ]
Feagan, B. [7 ]
Marano, C. [8 ]
Strauss, R. [8 ]
Johanns, J. [8 ]
Zhang, H. [8 ]
Padgett, L. [8 ]
Adedokun, O. J. [8 ]
Colombel, J. -F. [9 ]
Collins, J. [10 ]
Rutgeerts, P. [11 ]
Tarabar, D. [12 ]
机构：
[1] Univ Klin Innere Med III, Vienna, Austria
[2] McMaster Univ, Vienna, Austria
[3] Univ Klin Innere Med III, Hamilton, Austria
[4] McMaster Univ, Hamilton, Austria
[5] Alfred Hosp, Melbourne, Vic, Australia
[6] Univ Calif San Diego, Div Gastroenterol, La Jolla, CA 92093 USA
[7] Univ Western Ontario, Robarts Res Inst, Robarts Clin Trials Inc, London, ON, Canada
[8] Janssen R&D LLC, Spring House, PA USA
[9] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[10] Oregon Hlth & Sci Univ, Dept Gastroenterol, Portland, OR USA
[11] Univ Hosp Gasthuisberg, Dept Haematol, Leuven, Netherlands
[12] Mil Med Acad, Dept Gastroenterol & Hepatol, Belgrade 11002, Serbia
来源：
JOURNAL OF CROHNS & COLITIS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P307
引用
收藏
页码：S248 / S249
页数：2
相关论文
共 50 条
  • [21] COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Betts, Keith
    Eren, Devrim
    Tang, Wenxi
    Yin, Lei
    Gupte-Singh, Komal
    GASTROENTEROLOGY, 2022, 162 (07) : S603 - S603
  • [22] Pharmacokinetics of Adalimumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
    Awni, Walid M.
    Eckert, Doerthe
    Sharma, Shringi
    Mostafa, Nael M.
    Noertersheuser, Peter A.
    Pradhan, Rajendra S.
    Robinson, Anne
    Sandborn, William
    Hanauer, Stephen B.
    Colombel, Jean-Frederic
    Thakkar, Roopal
    GASTROENTEROLOGY, 2013, 144 (05) : S229 - S229
  • [23] Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis
    Taxonera, Carlos
    Iborra, Marisa
    Maia Bosca-Watts, Marta
    Rubio, Saioa
    Nantes, Oscar
    Higuera, Rebeca
    Bertoletti, Federico
    Martinez-Montiel, Pilar
    Sierra-Ausin, Monica
    Mancenido, Noemi
    Lazar Perez-Calle, Jose
    Algaba, Alicia
    Olivares, David
    Alba, Cristina
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1297 - 1304
  • [24] Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis
    Adedokun, Omoniyi J.
    Xu, Zhenhua
    Liao, Sam
    Strauss, Richard
    Reinisch, Walter
    Feagan, Brian G.
    Sandborn, William J.
    CLINICAL THERAPEUTICS, 2020, 42 (01) : 157 - 174
  • [25] A Multicenter Open-Label Study Assessing Pharmacokinetics, Efficacy, and Safety of Subcutaneous Golimumab in Pediatric Subjects with Moderately-Severely Active Ulcerative Colitis
    Hyams, Jeffrey
    Griffiths, Anne
    Veereman, Genevieve
    Turner, Dan
    Chan, Daphne
    Adedokun, Omoniyi
    Damaraju, Lakshmi
    Strauss, Richard
    INFLAMMATORY BOWEL DISEASES, 2016, 22 : S39 - S40
  • [26] Long-term Safety of Ozanimod in Patients with Moderately to Severely Active Ulcerative Colitis (UC) and Relapsing Multiple Sclerosis (RMS) Studies
    Rubin, David T.
    Wolf, Douglas C.
    Alekseeva, Olga
    Charles, Lorna
    Afsari, Sonia
    Petersen, Ann Katrin
    Sheffield, James
    Li, Hongjuan
    Silva, Diego
    Lublin, Fred D.
    Cree, Bruce
    Cohen, Jeffrey
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S396 - S396
  • [27] A Multi-Center Open-Label Study Assessing Pharmacokinetics, Efficacy, and Safety of Subcutaneous Golimumab in Pediatric Patients With Moderately-Severely Active Ulcerative Colitis
    Hyams, Jeffrey S.
    Griffiths, Anne M.
    Veereman, Gigi
    Turner, Dan
    Chan, Daphne
    Adedokun, Omoniyi J.
    Padgett, Lakshmi
    Strauss, Rick
    GASTROENTEROLOGY, 2016, 150 (04) : S132 - S132
  • [28] A Phase 2/3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Subcutaneous Golimumab Induction Therapy in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT SC
    Sandborn, W. J.
    Feagan, B. G.
    Marano, C. W.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Colombel, J.
    Reinisch, W.
    Gibson, P.
    Collins, J.
    Jarnerot, G. A.
    Rutgeerts, P. J.
    GASTROENTEROLOGY, 2012, 142 (05) : S161 - S161
  • [29] The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
    Shin, S. Shin
    Park, S. J.
    Kim, Y.
    Im, J. P.
    Kim, H. J.
    Lee, K. M.
    Kim, J. W.
    Jung, S. A.
    Lee, J.
    Kang, S. B.
    Shin, S. J.
    Kim, E. S.
    Kim, Y. S.
    Kim, T. O.
    Kim, H. S.
    Park, D. I.
    Kim, H. K.
    Kim, E. S.
    Kim, Y. H.
    Kim, D. H.
    Teng, D.
    Kim, J. H.
    Kim, W. Y.
    Choi, C. H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S432 - S432
  • [30] Pharmacokinetics, immunogenicity and clinical outcomes of golimumab from the PURSUIT PEDS ulcerative colitis study long-term (through week 126) extension
    Hyams, J.
    O'Brien, C. D.
    Padgett, L.
    Rosh, J.
    Turner, D.
    Veereman, G.
    Griffiths, A.
    Heyman, M. B.
    Wahbeh, G.
    Adedokun, J.
    Strauss, R.
    Chan, D.
    Lynch, J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S304 - S305
12345